Papers/PMID:41943502
Safety of 8-Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Study.
Phytotherapy research : PTR2026The record
1 finding drawn from this paper, on 1 compound across 1 endpoint, 1 of them null.
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Withania somnifera — no detected effect on adverse event occurrence (oral or enteral supplement)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“The relative risk (RR) of experiencing at least one AE in the ARE group compared with PL was 0.67 (95% CI: 0.42–1.06), suggesting a numerically lower, though not statistically significant, AE incidence in the Ashwagandha group.”
Quoted verbatim from Safety of 8-Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Study.. - Study
- RCT
- Participants
- 1,002
- Duration
- 8 weeks
- Dose
- 300 mg capsule orally twice daily (600 mg/day), after breakfast and after dinner, for 8 weeks
- Population
- adults aged 18 to 65 with reported stress and anxiety (HAM-A total 14-30, Cohen PSS 13 or above), enrolled at 15 sites across India, Australia, the United States, Portugal and Africa
Effect 0.67 risk ratio, 95% CI 0.42 to 1.06
Safety of 8-Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Study.2026PMID:41943502Industry funded